Nitric oxide in cancer metastasis

Cancer Letters

Volumn 353, Issue 1, 2014, Pages 1-7

  Cheng, Huiwen ^a   Wang, Lei ^a   Mollica, Molly ^a   Re, Anthony T ^b   Wu, Shiyong ^a   Zuo, Li ^b  

^a OHIO UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Hypoxia; INOS; NSAIDs; Signaling; Tumor

Indexed keywords

COLLAGENASE 3; CYCLIC GMP; CYCLOOXYGENASE 2; GELATINASE B; INTEGRIN; INTERSTITIAL COLLAGENASE; NITRIC OXIDE; PROTEIN KINASE C; STROMELYSIN; STROMELYSIN 2; ANTINEOPLASTIC AGENT; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL ADHESION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; CELL HYPOXIA; DISEASE COURSE; DRUG EFFECT; INOS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NSAIDS; PATHOLOGY; PROGNOSIS; REVIEW; SIGNALING; VASCULARIZATION;

HYPOXIA; INOS; NSAIDS; SIGNALING; TUMOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE DONORS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84908372432     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.014     Document Type: Review

References (87)

1. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3(6):453-458.
2. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6(6):449-458.
3. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006, 12(8):895-904.
4. Coulter J.A., McCarthy H.O., Xiang J., Roedl W., Wagner E., Robson T., Hirst D.G. Nitric oxide-a novel therapeutic for cancer. Nitric Oxide 2008, 19(2):192-198.
5. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19(5):711-721.
6. Williams E.L., Djamgoz M.B. Nitric oxide and metastatic cell behaviour. BioEssays 2005, 27(12):1228-1238.
7. Dong Z., Staroselsky A.H., Qi X., Xie K., Fidler I.J. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 1994, 54(3):789-793.
8. Xie K., Huang S., Dong Z., Juang S.H., Gutman M., Xie Q.W., Nathan C., Fidler I.J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 1995, 181(4):1333-1343.
9. Xie K., Dong Z., Fidler I.J. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J. Leukoc. Biol. 1996, 59(6):797-803.
10. Tozer G.M., Prise V.E., Chaplin D.J. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with l-arginine. Cancer Res. 1997, 57(5):948-955.
11. Felley-Bosco E. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev. 1998, 17(1):25-37.
12. Bing R.J., Miyataka M., Rich K.A., Hanson N., Wang X., Slosser H.D., Shi S.R. Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin. Cancer Res. 2001, 7(11):3385-3392.
13. Ishikawa T., Yoshida N., Higashihara H., Inoue M., Uchiyama K., Takagi T., Handa O., Kokura S., Naito Y., Okanoue T., et al. Different effects of constitutive nitric oxide synthase and heme oxygenase on pulmonary or liver metastasis of colon cancer in mice. Clin. Exp. Metastasis 2003, 20(5):445-450.
14. Le X., Wei D., Huang S., Lancaster J.R. Xie K: Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc. Natl. Acad. Sci. USA 2005, 102(24):8758-8763.
15. Mocellin S. Nitric oxide: cancer target or anticancer agent?. Curr. Cancer Drug Targets 2009, 9(2):214-236.
16. Moncada S., Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 2006, 147(Suppl 1):S193-S201.
17. Riddell D.R., Owen J.S. Nitric oxide and platelet aggregation. Vitam. Horm. 1999, 57:25-48.
18. Wink D.A., Hines H.B., Cheng R.Y., Switzer C.H., Flores-Santana W., Vitek M.P., Ridnour L.A., Colton C.A. Nitric oxide and redox mechanisms in the immune response. J. Leukoc. Biol. 2011, 89(6):873-891.
19. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6(7):521-534.
20. DeNardo D.G., Johansson M., Coussens L.M. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008, 27(1):11-18.
21. Tsuruo T., Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2008, 84(6):189-198.
22. Forstermann U., Schmidt H.H., Pollock J.S., Sheng H., Mitchell J.A., Warner T.D., Nakane M., Murad F. Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem. Pharmacol. 1991, 42(10):1849-1857.
23. Radomski M.W., Jenkins D.C., Holmes L., Moncada S. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res. 1991, 51(22):6073-6078.
24. Zafirellis K., Zachaki A., Agrogiannis G., Gravani K. Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer. APMIS 2010, 118(2):115-124.
25. Niu X.J., Wang Z.R., Wu S.L., Geng Z.M., Zhang Y.F., Qing X.L. Relationship between inducible nitric oxide synthase expression and angiogenesis in primary gallbladder carcinoma tissue. World J. Gastroenterol. 2004, 10(5):725-728.
26. Lahiri M., Martin J.H. Nitric oxide decreases motility and increases adhesion in human breast cancer cells. Oncol. Rep. 2009, 21(2):275-281.
27. Juang S.H., Xie K., Xu L., Wang Y., Yoneda J., Fidler I.J. Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma. Cancer Biother. Radiopharm. 1997, 12(3):167-175.
28. Wang B., Wei D., Crum V.E., Richardson E.L., Xiong H.H., Luo Y., Huang S., Abbruzzese J.L., Xie K. A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 2003, 22(12):1771-1782.
29. Xie K., Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic. Biol. Med. 2003, 34(8):969-986.
30. Worthington J., McCarthy H.O., Barrett E., Adams C., Robson T., Hirst D.G. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J. Gene Med. 2004, 6(6):673-680.
31. Tell R.T., Sydiskis R.J., Isaacs R.D., Davidson W.M. Long-term cytotoxicity of orthodontic direct-bonding adhesives. Am. J. Orthod. Dentofacial. Orthop. 1988, 93(5):419-422.
32. Califice S., Castronovo V., Van Den Brule F. Galectin-3 and cancer (Review). Int. J. Oncol. 2004, 25(4):983-992.
33. Moon B.K., Lee Y.J., Battle P., Jessup J.M., Raz A., Kim H.R. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am. J. Pathol. 2001, 159(3):1055-1060.
34. Song Y.K., Billiar T.R., Lee Y.J. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am. J. Pathol. 2002, 160(3):1069-1075.
35. Sayed-Ahmad M.M., Mohamad M.A. Contribution of nitric oxide and epidermal growth factor receptor in anti-metastatic potential of paclitaxel in human liver cancer cell (HebG2). J. Egypt Natl. Canc. Inst. 2005, 17(1):35-41.
36. Ferrer P., Asensi M., Priego S., Benlloch M., Mena S., Ortega A., Obrador E., Esteve J.M., Estrela J.M. Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J. Biol. Chem. 2007, 282(5):2880-2890.
37. Muntane J., De la Rosa A.J., Marin L.M., Padillo F.J. Nitric oxide and cell death in liver cancer cells. Mitochondrion 2013, 13(3):257-262.
38. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell Mol. Med. 2009, 13(7):1221-1227.
39. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., Bus C.J., Kadkhoda K., Wiechec E., Halayko A.J., et al. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46(8):497-510.
40. Ridnour L.A., Thomas D.D., Switzer C., Flores-Santana W., Isenberg J.S., Ambs S., Roberts D.D., Wink D.A. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008, 19(2):73-76.
41. Chambers A.F., MacDonald I.C., Schmidt E.E., Koop S., Morris V.L., Khokha R., Groom A.C. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 1995, 14(4):279-301.
42. Ponta H., Sleeman J., Herrlich P. Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochim. Biophys. Acta 1994, 1198(1):1-10.
43. Pass H.I. Biology of metastatic disease. Semin. Thorac. Cardiovasc. Surg. 2002, 14(1):10-17.
44. Shiomi T., Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003, 22(2-3):145-152.
45. Poincloux R., Lizarraga F., Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J. Cell Sci. 2009, 122(Pt 17):3015-3024.
46. Gupta S.K., Vlahakis N.E. Integrin alpha9beta1 mediates enhanced cell migration through nitric oxide synthase activity regulated by Src tyrosine kinase. J. Cell Sci. 2009, 122(Pt 12):2043-2054.
47. St-Pierre Y., Couillard J., Van Themsche C. Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases. Expert Opin. Ther. Targets 2004, 8(5):473-489.
48. Thompson E.W., Yu M., Bueno J., Jin L., Maiti S.N., Palao-Marco F.L., Pulyaeva H., Tamborlane J.W., Tirgari R., Wapnir I., et al. Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res. Treat. 1994, 31(2-3):357-370.
49. Ishii Y., Ogura T., Tatemichi M., Fujisawa H., Otsuka F., Esumi H. Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int. J. Cancer 2003, 103(2):161-168.
50. Jespersen C., Doller A., Akool el S., Bachmann M., Muller R., Gutwein P., Muhl H., Pfeilschifter J., Eberhardt W. Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells. J. Cell. Physiol. 2009, 219(2):276-287.
51. Sun Y., Liu J., Qian F., Xu Q. Nitric oxide inhibits T cell adhesion and migration by down-regulation of beta1-integrin expression in immunologically liver-injured mice. Int. Immunopharmacol. 2006, 6(4):616-626.
52. Roberts W., Riba R., Homer-Vanniasinkam S., Farndale R.W., Naseem K.M. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J. Thromb. Haemost. 2008, 6(12):2175-2185.
53. Conran N., Gambero A., Ferreira H.H., Antunes E., de Nucci G. Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface. Biochem. Pharmacol. 2003, 66(1):43-50.
54. Yudoh K., Matsui H., Tsuji H. Nitric oxide induced by tumor cells activates tumor cell adhesion to endothelial cells and permeability of the endothelium in vitro. Clin. Exp. Metastasis 1997, 15(6):557-567.
55. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29(6 Suppl 16):15-18.
56. Sun M.H., Han X.C., Jia M.K., Jiang W.D., Wang M., Zhang H., Han G., Jiang Y. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J. Gastroenterol. 2005, 11(38):5931-5937.
57. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl Cancer Inst. 1998, 90(8):587-596.
58. Jiang T., Yu J.T., Zhu X.C., Zhang Q.Q., Tan M.S., Cao L., Wang H.F., Lu J., Gao Q., Zhang Y.D., et al. Angiotensin-(1-7) induces cerebral ischemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br. J. Pharmacol. 2014.
59. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., Kim J., Kim Y.M., Kwon Y.G. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114(14):3117-3126.
60. Kolluru G.K., Sinha S., Majumder S., Muley A., Siamwala J.H., Gupta R., Chatterjee S. Shear stress promotes nitric oxide production in endothelial cells by sub-cellular delocalization of eNOS: a basis for shear stress mediated angiogenesis. Nitric Oxide 2010, 22(4):304-315.
61. Bessa X., Elizalde J.I., Mitjans F., Pinol V., Miquel R., Panes J., Piulats J., Pique J.M., Castells A. Leukocyte recruitment in colon cancer: role of cell adhesion molecules, nitric oxide, and transforming growth factor beta1. Gastroenterology 2002, 122(4):1122-1132.
62. Spiecker M., Darius H., Kaboth K., Hubner F., Liao J.K. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J. Leukoc. Biol. 1998, 63(6):732-739.
63. Huang H., Lavoie-Lamoureux A., Moran K., Lavoie J.P. IL-4 stimulates the expression of CXCL-8, E-selectin, VEGF, and inducible nitric oxide synthase mRNA by equine pulmonary artery endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292(5):L1147-L1154.
64. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 2005, 5(9):735-743.
65. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001, 61(5):1786-1790.
66. Yasuoka H., Tsujimoto M., Yoshidome K., Nakahara M., Kodama R., Sanke T., Nakamura Y. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008, 8:340.
67. Nakamura Y., Yasuoka H., Tsujimoto M., Yoshidome K., Nakahara M., Nakao K., Nakamura M., Kakudo K. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin. Cancer Res. 2006, 12(4):1201-1207.
68. Baek J.H., Jang J.E., Kang C.M., Chung H.Y., Kim N.D., Kim K.W. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000, 19(40):4621-4631.
69. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., Lim S.K., Sze S.K. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 2010, 9(6):1085-1099.
70. Postovit L.M., Adams M.A., Lash G.E., Heaton J.P., Graham C.H. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int. J. Cancer 2004, 108(1):47-53.
71. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J. Biol. Chem. 1999, 274(13):9038-9044.
72. Sandau K.B., Zhou J., Kietzmann T., Brune B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem. 2001, 276(43):39805-39811.
73. Siemens D.R., Heaton J.P., Adams M., Kawakami J., Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74(4):878-883.
74. Chen C.N., Hsieh F.J., Cheng Y.M., Chang K.J., Lee P.H. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer. J. Surg. Oncol. 2006, 94(3):226-233.
75. Tyryshkin A., Gorgun F.M., Abdel Fattah E., Mazumdar T., Pandit L., Zeng S. Eissa NT: Src kinase-mediated phosphorylation stabilizes inducible nitric-oxide synthase in normal cells and cancer cells. J. Biol. Chem. 2010, 285(1):784-792.
76. Burke A.J., Sullivan F.J., Giles F.J., Glynn S.A. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013, 34(3):503-512.
77. Burgaud J.L., Ongini E., Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. N. Y. Acad. Sci. 2002, 962:360-371.
78. Stolfi C., De Simone V., Pallone F., Monteleone G. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int. J. Mol. Sci. 2013, 14(9):17972-17985.
79. Vaish V., Piplani H., Rana C., Vaiphei K., Sanyal S.N. NSAIDs may regulate EGR-1-mediated induction of reactive oxygen species and non-steroidal anti-inflammatory drug-induced gene (NAG)-1 to initiate intrinsic pathway of apoptosis for the chemoprevention of colorectal cancer. Mol. Cell. Biochem. 2013, 378(1-2):47-64.
80. Domingo E., Church D.N., Sieber O., Ramamoorthy R., Yanagisawa Y., Johnstone E., Davidson B., Kerr D.J., Tomlinson I.P.M., Midgley R. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 2013, 31(34):U4234-U4297.
81. Cheng H., Mollica M.Y., Lee S.H., Wang L., Velazquez-Martinez C.A., Wu S. Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-NSAIDs) on melanoma cell adhesion. Toxicol. Appl. Pharmacol. 2012, 264(2):161-166.
82. Williams J.L., Borgo S., Hasan I., Castillo E., Traganos F., Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res. 2001, 61(8):3285-3289.
83. Kashfi K., Ryann Y., Qiao L.L., Williams J.L., Chen J., Del Soldato P., Traganos F., Rigas B. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J. Pharm. Exp. Ther. 2002, 303(3):1273-1282.
84. Olson S.Y., Garban H.J. Regulation of apoptosis-related genes by nitric oxide in cancer. Nitric Oxide 2008, 19(2):170-176.
85. Pan X., Wang X., Lei W., Min L., Yang Y., Wang X., Song J. Nitric oxide suppresses transforming growth factor-beta1-induced epithelial-to-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 2009, 50(5):1577-1587.
86. Brune B. Nitric oxide: NO apoptosis or turning it ON?. Cell Death Differ. 2003, 10(8):864-869.
87. Adams D.J., Levesque M.C., Weinberg J.B., Smith K.L., Flowers J.L., Moore J., Colvin O.M., Silber R. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 2001, 15(12):1852-1859.